Found: 31
Select item for more details and to access through your institution.
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1021, doi. 10.1007/s10637-022-01287-7
- By:
- Publication type:
- Article
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1137, doi. 10.1007/s10637-022-01264-0
- By:
- Publication type:
- Article
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1125, doi. 10.1007/s10637-022-01257-z
- By:
- Publication type:
- Article
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1153, doi. 10.1007/s10637-022-01288-6
- By:
- Publication type:
- Article
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1042, doi. 10.1007/s10637-022-01286-8
- By:
- Publication type:
- Article
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1011, doi. 10.1007/s10637-022-01285-9
- By:
- Publication type:
- Article
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 977, doi. 10.1007/s10637-022-01284-w
- By:
- Publication type:
- Article
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1117, doi. 10.1007/s10637-022-01283-x
- By:
- Publication type:
- Article
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 962, doi. 10.1007/s10637-022-01282-y
- By:
- Publication type:
- Article
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 953, doi. 10.1007/s10637-022-01280-0
- By:
- Publication type:
- Article
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1095, doi. 10.1007/s10637-022-01279-7
- By:
- Publication type:
- Article
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1001, doi. 10.1007/s10637-022-01277-9
- By:
- Publication type:
- Article
Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 944, doi. 10.1007/s10637-022-01278-8
- By:
- Publication type:
- Article
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1087, doi. 10.1007/s10637-022-01276-w
- By:
- Publication type:
- Article
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 990, doi. 10.1007/s10637-022-01274-y
- By:
- Publication type:
- Article
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 934, doi. 10.1007/s10637-022-01275-x
- By:
- Publication type:
- Article
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 922, doi. 10.1007/s10637-022-01272-0
- By:
- Publication type:
- Article
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1080, doi. 10.1007/s10637-022-01271-1
- By:
- Publication type:
- Article
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1141, doi. 10.1007/s10637-022-01270-2
- By:
- Publication type:
- Article
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1066, doi. 10.1007/s10637-022-01269-9
- By:
- Publication type:
- Article
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1032, doi. 10.1007/s10637-022-01267-x
- By:
- Publication type:
- Article
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 905, doi. 10.1007/s10637-022-01266-y
- By:
- Publication type:
- Article
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 895, doi. 10.1007/s10637-022-01265-z
- By:
- Publication type:
- Article
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 884, doi. 10.1007/s10637-022-01263-1
- By:
- Publication type:
- Article
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1051, doi. 10.1007/s10637-022-01253-3
- By:
- Publication type:
- Article
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1146, doi. 10.1007/s10637-022-01261-3
- By:
- Publication type:
- Article
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
- Published in:
- 2022
- By:
- Publication type:
- Letter
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1133, doi. 10.1007/s10637-022-01259-x
- By:
- Publication type:
- Article
ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 875, doi. 10.1007/s10637-022-01258-y
- By:
- Publication type:
- Article
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1106, doi. 10.1007/s10637-022-01221-x
- By:
- Publication type:
- Article